Company Description
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States.
The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies.
It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications.
In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 111 |
| CEO | Dr. Robert S. Langer Jr., Ph.D. |
Contact Details
Address: 6 Tide Street, Suite 400 Boston, Massachusetts 02210 United States | |
| Phone | 617-482-2333 |
| Website | puretechhealth.com |
Stock Details
| Ticker Symbol | PRTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782999 |
| CUSIP Number | 746237106 |
| ISIN Number | US7462371060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Founder, Senior Advisor and Board Observer |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder and Non-Executive Director |
| Dr. Eric Elenko Ph.D. | President, Chief Innovation and Strategy Officer |
| Dr. David R. Elmaleh Ph.D. | Co-Founder and Senior Advisor |
| Allison Mead Talbot | Head of Communications and Investor Relations |
| Spencer Ball | Senior Vice President of Human Resources |
| Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
| Cheryl Murphy Ph.D. | Head of Grants Management and Strategy |
| Anita Terpstra J.D., Ph.D. | Senior Vice President and Head of Intellectual Property |
| Dilip Kodira | Head of Data Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Mar 19, 2024 | SC TO-C | Filing |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 18, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | 6-K | Report of foreign issuer |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | 6-K | Report of foreign issuer |
| Jan 4, 2024 | 6-K | Report of foreign issuer |